SpineAnalyzer™ is our flagship product and we invite you to try it out for a month to see the benefits it can bring to your clinical practice. SpineAnalyzer can improve quality of care in osteoporosis by helping you to identify patients who may benefit from treatment due to the presence of a vertebral fracture that might otherwise not be treated.

A prevalent vertebral fracture is a key risk factor for future fracture and is a key component of new diagnostic algorithms such as FRAX^®, which is changing the way that fracture risk is evaluated. However, vertebral fractures are often under-reported or missed altogether. SpineAnalyzer can provide the missing piece of the puzzle by helping assess vertebral deformities that may indicate osteoporotic fracture. SpineAnalyzer is easily incorporated into your women’s health radiology practice, will increase the utilization of your digital x-ray suite and will be instantly appreciated by your referring physicians.

Simply complete the short form on our evaluation sign-up page and we will send you download instructions for a fully functional evaluation version of the software.

Optasia Medical are pleased to announce that we will be exhibiting at the forthcoming Annual Scientific Meeting of the American College of Rheumatology in Chicago, 5-9 November 2011. Please come and see us at booth 1003.

We will be exhibiting our flagship product SpineAnalyzer™, for the assessment and documentation of vertebral deformities in patients at risk of osteoporosis. We invite you to visit us and to learn how SpineAnalyzer can improve quality of care in osteoporosis by helping to identify patients who may benefit from treatment due to the presence of a vertebral fracture that might otherwise not be treated. We will be offering a free 30-day evaluation of SpineAnalyzer to see the benefits that the software can make to your clinical practice.

To arrange a meeting during the show, please email acr2011@optasiamedical.com.

Nobody doubts the importance vertebral fractures have in predicting the risk for future osteoporotic fractures, most importantly hip fractures; the predictive value of vertebral fractures has been documented in numerous prospective studies around the world.

This finding has been recognized in the treatment guidelines of many clinical professional societies and independent health organizations such as the National Osteoporosis Foundation (NOF). The NOF guidelines stipulate that a vertebral fracture constitutes a diagnosis of osteoporosis, independent of bone density, and justifies treatment. The World Health Organization’s FRAX fracture risk assessment tool includes prevalent fractures, including radiographic vertebral fractures, as one of its seven clinical risk factors. In a 55 year old women, a prevalent vertebral fracture can increase the 10-year risk of another osteoporotic fracture almost two-fold (see table).

However, nobody talks about how vertebral fractures are found. Most vertebral fractures do not come to clinical attention, resulting in significant underdiagnosis and treatment of osteoporosis. This simple fact is starting to be picked up by commentators in the press. Recent editorials in the New York Times (by Jane E. Brody on June 27th, 2011) and USA Today (by Gail Sheehy on September 19th, 2011) encourage patients to ask their doctors about vertebral fractures and to ask them to perform a test that can find them.

Part of the problem currently is that there are no universally accepted standards on how to do this. Gail Sheehy refers to VFA (Vertebral Fracture Assessment) images, which are lateral spine radiographs obtained at low x-ray dose on a bone densitometer. However, VFA cannot be performed on all bone densitometers and is not universally reimbursed. When VFA is not available, conventional x-rays can serve the same purpose, and indeed, are more reliable for detecting mild vertebral fractures.

This is why we have developed SpineAnalyzer™, which physicians can use to document vertebral fractures on conventional x-rays and VFA images alike in a comprehensive, quantitative, objective and personalized way. SpineAnalyzer generates an easy-to-understand report much like a bone densitometry report, which can be shared with the patient.

It is refreshing to see a growing public awareness of osteoporosis and its consequences if left untreated, but there is still a huge amount of work to do to spread the message. Gail Sheehy refers to the NOF’s “Let’s Get Talking” campaign. We agree wholeheartedly and believe that being pro-active in finding vertebral fractures is a key part of the conversation.

Optasia Medical are pleased to announce that we will be exhibiting at the forthcoming Annual Meeting of The American Society of Bone and Mineral Research in San Diego, 16-20 September 2011. Please come and see us at booth 203.

We will be exhibiting our flagship product SpineAnalyzer™, for the assessment and documentation of vertebral deformities in patients at risk of osteoporosis. We invite you to visit us and to learn how SpineAnalyzer can improve quality of care in osteoporosis by helping to identify patients who may benefit from treatment due to the presence of a vertebral fracture that might otherwise not be treated. We will be offering a free 30-day evaluation of SpineAnalyzer to see the benefits that the software can make to your clinical practice.

To arrange a meeting during the show, please email asbmr2011@optasiamedical.com.

Optasia Medical are pleased to announce that we will be exhibiting our flagship product SpineAnalyzer™ at the forthcoming Annual Meeting of the Association for Medical Imaging Management (AHRA) in Dallas, 14-17 August 2011. Please come and see us at booth 931.

We invite you to visit us and to learn how SpineAnalyzer can improve quality of care in osteoporosis by helping to identify patients who may benefit from treatment due to the presence of a vertebral fracture that might otherwise not be treated.

A prevalent vertebral fracture is a key risk factor for future fracture and is a key component of new diagnostic algorithms such as FRAX^®, which is changing the way that fracture risk is evaluated. However, vertebral fractures are often under-reported or missed altogether. SpineAnalyzer can provide the missing piece of the puzzle by helping assess vertebral deformities that may indicate osteoporotic fracture.

SpineAnalyzer is easily incorporated into your women’s health radiology practice, will increase the utilization of your digital x-ray suite and will be instantly appreciated by your referring physicians.

To arrange a meeting during the show, please email ahra2011@optasiamedical.com.

Manchester, UK, and Sudbury, MA, May 31, 2011 — Optasia Medical Inc., a leading provider of imaging productivity tools today announced that it has joined the National Bone Health Alliance (NBHA). Optasia Medical’s premier product, SpineAnalyzer™, is an innovative workflow tool for the quantitative assessment of vertebral deformities in patients at risk of osteoporotic fractures. The output of the device may be used by physicians to assist in the diagnosis of vertebral fractures, a key factor to determine if therapeutic intervention is indicated.

The ability to accurately assess vertebral fractures is rapidly gaining an increased role in clinical practice.
The National Osteoporosis Foundation’s Clinician’s Guide to Prevention and Treatment of Osteoporosis states that patients with a clinical or morphometric vertebral fracture should be considered for treatment even in cases when their bone density is not at a level considered osteoporotic. In addition, the Guide recommends using the World Health Organization’s Fracture Risk Assessment Tool (FRAX) to estimate a patient’s 10-year fracture risk, where previous fractures, including vertebral fractures, have a significant impact on a patient’s risk.

Established in 2010, the National Bone Health Alliance (NBHA) is a public-private partnership that brings
together the expertise and resources of various partners across a broad spectrum to promote bone health
and prevent disease; improve diagnosis and treatment of bone disease; and enhance bone research,
surveillance and evaluation. Founding members include the American Academy of Orthopedic Surgeons,
American Society for Bone and Mineral Research, Health Monitor Network, National Osteoporosis
Foundation, the Paget Foundation for Paget’s Disease of Bone and Related Disorders and the Osteogenesis
Imperfecta Foundation. For more information on the NBHA, visit www.nbha.org.

“Optasia Medical is very pleased to have joined twenty-two other leading healthcare organizations and
providers in support of the initiatives of the NBHA” said Jim DePass, Optasia Medical’s Vice President of
Business Development for the US. “In 2005, over 2 million osteoporosis-related fractures occurred in the
US, a number expected to reach 3 million by 2025. The costs related to these fractures were $16.9 billion
in 2005 and are predicted to rise to $25 billion by 2025. Despite the availability of bone densitometry and
pharmacological therapies, the incidence and costs related to osteoporosis have not decreased. What we
sorely need to reduce these costs is more public awareness of osteoporosis in combination with better
tools for diagnosis and treatment and that is the goal of the NBHA.”

Contact:

James DePass, VP Business Development, US
Tel: +1 (608) 469-6259
Email: james.depass@optasiamedical.com

Optasia Medical are pleased to announce that we will be exhibiting at the forthcoming Annual European Congress of Rheumatology in London, 25-28 May 2011. Please come and see us at booth 435.

We will be exhibiting SpineAnalyzer™, for the assessment and documentation of vertebral deformities in osteoporosis, and RapidScore™, for the rapid documentation of disease progression in hand and foot x-rays of patients suffering from rheumatoid arthritis or psoriatic arthritis.

To arrange a meeting during the show, please email eular2011@optasiamedical.com.

Manchester, UK, and Sudbury, MA, February 3, 2011 — Optasia Medical, a leading image analysis software applications provider today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for SpineAnalyzer™, an innovative workflow tool for the quantitative assessment of vertebral deformities in patients at risk of osteoporosis. The output of the device may be used by physicians to assist in the diagnosis of vertebral fractures, a key factor to determine if therapeutic intervention is indicated.

“The aging population and resulting increase in the number of patients suffering from osteoporosis is placing an ever increasing burden on healthcare systems, yet the existing tools to assist with the diagnosis of vertebral fractures are inadequate”, said Peter Steiger, Optasia Medical’s Chief Executive Officer. “In 2005, over 2 million osteoporosis-related fractures occurred in the US, a number expected to reach 3 million by 2025. The costs related to these fractures were $16.9 billion in 2005 and are predicted to rise to $25 billion by 2025. Despite the availability of bone densitometry and pharmacological therapies, the incidence and costs related to osteoporosis have not decreased.”

Alan Brett, Optasia Medical’s Founder and Chief Technology Officer added: “Only 25% of vertebral fractures are clinically apparent, and 20% of women who are not considered osteoporotic by bone densitometry have vertebral fractures. The National Osteoporosis Foundation’s Clinician’s Guide to Prevention and Treatment of Osteoporosis (PDF) states that patients with a clinical or morphometric vertebral fracture should be considered for treatment. In addition, the Guide recommends using the World Health Organization’s Fracture Risk Assessment Tool (FRAX) to estimate a patient’s 10-year fracture risk, where previous fractures, including vertebral fractures, have a significant impact on a patient’s risk.”

Harry K. Genant, Professor Emeritus of Radiology, Orthopedic Surgery, Medicine, and Epidemiology at the University of California San Francisco, commented: “I believe that, in the hands of physicians, the SpineAnalyzer Program represents a major step forward in facilitating and standardizing their assessment of vertebral fractures across a broad spectrum of osteoporosis clinical and research practice.”

“A vertebral fracture, found on a radiograph, is the most important risk factor for future fracture” said Dr. Steven R. Cummings, Professor of Medicine and Epidemiology, at the University of California in San Francisco. “Patients who have evidence of a fracture on x-ray should receive effective drug therapy to prevent additional fractures. However, most vertebral fractures are missed by current clinical assessments and reports. We have used SpineAnalyzer to assess hundreds of spine films and I am impressed that it would change practice by making accurate assessment of vertebral deformities an easy, routine part of radiologic practice; this would substantially improve patient care.”

Optasia Medical has recently established distribution capability in the U.S. and plans a formal launch of SpineAnalyzer.

For more information on Optasia Medical and SpineAnalyzer, please visit www.optasiamedical.com.

About Optasia Medical

Optasia makes software that facilitates the reading of x-rays for the management of musculoskeletal diseases. Our products are used in clinical trials and by physicians to identify and monitor patients who will benefit from treatment. With Optasia Medical’s automated workflow tools, x-rays can be evaluated more rapidly, more accurately and more reproducibly. Optasia Medical’s current offerings include SpineAnalyzer™, a PACS/DICOM workstation software solution for the assessment and documentation of vertebral deformities in osteoporosis, KneeTool™, for the quantification of joint space narrowing in Osteoarthritis, and RapidScore™, for the rapid documentation of disease progression in hand and foot x-rays of patients suffering from rheumatoid arthritis. For more information about the software applications that Optasia can provide visit: www.optasiamedical.com.

FOR IMMEDIATE RELEASE

Contacts:

Peter Steiger, CEO

Tel:      +1 508 405 4392

Email:  peter.steiger@optasiamedical.com